Exclusive event for international investors
ISAs, investment trusts and OEICs
Set to be included into the FTSE 250
Cash exit offer increased to 15%
Managed by O'Hara and Ross
Janus Henderson Credit Risk Monitor
Portfolio Managers Andy Acker and Agustin Mohedas explain why shares of companies delivering next-generation therapies for inflammation and immunology (I&I) disorders could have plenty of room to run.